PT - JOURNAL ARTICLE AU - Doris Kafita AU - Victor Daka AU - Panji Nkhoma AU - Mildred Zulu AU - Ephraim Zulu AU - Rabecca Tembo AU - Zifa Ngwira AU - Florence Mwaba AU - Musalula Sinkala AU - Sody Munsaka TI - High ELF4 Expression in Human Cancers is Associated with Worse Disease Outcomes and Increased Resistance to Anticancer Agents AID - 10.1101/2020.05.16.20104380 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.16.20104380 4099 - http://medrxiv.org/content/early/2020/05/20/2020.05.16.20104380.short 4100 - http://medrxiv.org/content/early/2020/05/20/2020.05.16.20104380.full AB - The malignant phenotype of tumour cells is fuelled by changes in the expression of various transcription factors, which include some of the well-studied proteins such as p53 and Myc. Despite significant progress made, little is known about several other transcription factors, including ELF4, and how they help shape the oncogenic processes that occur in cancer cells. To this end, we performed a bioinformatics analysis to facilitate a detailed understanding of how the transcriptional variations of ELF4 in human cancers are related to disease outcomes and the cancer cell drug responses. Here, using mRNA transcription data of ELF4 from the Cancer Genome Atlas pan-cancer project of 9,350 samples, we identify two groups of patient’s tumours: those that expressed high ELF4 transcripts and those that expressed low ELF4 transcripts across 32 different human cancers. We uncover that patients segregated into these two groups are associated with different clinical outcomes. Further, we found that, besides being associated with comparatively worse disease outcomes, tumours that express high ELF4 mRNA transcript tend to be of a higher-grade, afflict a significantly older patient population and have a significantly higher mutation burden. By analysing dose-response profiles to 397 anti-cancer drugs of 612 well-characterised human cancer cell lines from the Genomics of Drug Sensitivity in Cancer, we discover that cell lines that express high ELF4 mRNA transcript are significantly less responsive to 129 anti-cancer drugs. Collectively our analyses have shown that, across the 32 different human cancers, the patients afflicted with tumours that overexpress ELF4 tended to have a more aggressive disease that is also is more likely more refractory to most anti-cancer drugs, a finding upon which we could devise novel categorisation of patient tumours, treatment and prognostic strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot ApplicableAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the following repositories: cBioPortal (https://www.cbioportal.org/), Genomics of Drug Sensitivity in Cancer (https://www.cancerrxgene.org/), and the Cancer Cell Line Encyclopaedia (https://portals.broadinstitute.org/ccle/).